Assessment of Admission to the ICU of Onco-hematological Patients.

November 1, 2023 updated by: Elena Cuenca Fito, University Hospital A Coruña

Assessment of Admission to the ICU of Onco-hematological Patients. Income Patterns and Results.

Multicenter, observational and prospective study.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

The data collection period will include 6 consecutive months, starting from the date of acceptance or conformity of the CEIC. Or, until an adequate sample size is reached that guarantees the statistical relevance of said analysis. All patients will subsequently be followed up 3 months after discharge from the ICU.

Study Type

Observational

Enrollment (Estimated)

800

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

Patients with a diagnosis of solid organ or hematological tumor who are admitted to the hospital and require ICU evaluation.

Description

Inclusion Criteria:

  • Adults
  • Solid organ tumor or hematological malignancy,

Exclusion Criteria:

-under 18 years old

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients admitted to the ICU.
Other: There is no intervention.
There is no intervention in the study.
Patients who are not admitted to the ICU.
Other: There is no intervention.
There is no intervention in the study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Hospital mortality.
Time Frame: During the 6 months of the study.
During the 6 months of the study.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital A Coruña

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2024

Primary Completion (Estimated)

July 1, 2024

Study Completion (Estimated)

September 1, 2024

Study Registration Dates

First Submitted

July 11, 2023

First Submitted That Met QC Criteria

November 1, 2023

First Posted (Actual)

November 2, 2023

Study Record Updates

Last Update Posted (Actual)

November 2, 2023

Last Update Submitted That Met QC Criteria

November 1, 2023

Last Verified

October 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 23772377

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe